Remus Pharmaceuticals P/E Ratio
Remus Pharmaceuticals (REMUS) P/E ratio is 20.06 (Moderate), EPS (TTM) ₹65.21, current price ₹ on None — High - Growth expectations or overvalued. For live price, revenue and the complete fundamental profile, see REMUS company profile.
Current P/E Ratio
20.06
Moderate Valuation
High - Growth expectations or overvalued
Current Valuation Metrics
P/E Ratio
20.06
Current Price
₹
EPS (TTM)
₹65.21
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
49.16
Sector Median
27.18
Sector Rank
#11 of 139
Sector Percentile
7.9%
REMUS P/E Ratio — Valuation Signal & Historical Context
Remus Pharmaceuticals P/E 20.06 — signal: Overvalued. Analyse REMUS institutional holdings to track promoter, FII and institutional holdings.
- Trading at discount to sector average PE of 49.16
REMUS vs Healthcare Peers — P/E Ratio Comparison
Remus Pharmaceuticals P/E 20.06 vs Healthcare average 49.16, median 27.18 — range 1.17–869.57.
Sector Average
49.16
Sector Median
27.18
Lowest P/E
1.17
Highest P/E
869.57
Companies
139
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Welcure Drugs & Pharmace… | WELCURE | 1.17 | ₹43 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Ind Swift Laboratories | INDSWFTLAB | 4.93 | ₹1,136 | Low |
| Amwill Health Care | AMWILL | 5.67 | ₹64 | Low |
| Medicamen Organics | MEDIORG | 6.4 | ₹27 | Low |
| Zenith Drugs | ZENITHDRUG | 6.83 | ₹69 | Low |
| Unichem Laboratories | UNICHEMLAB | 7.99 | ₹2,364 | Low |
| Galaxy Medicare | GML | 8.78 | ₹31 | Low |
| Brooks Laboratories | BROOKS | 9.86 | ₹211 | Low |
| Accretion Pharmaceuticals | ACCPL | 10.92 | ₹78 | Low |